GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
F

Firebrick Pharma FRE.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.03

0.00%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Firebrick Pharma — daily ASX:FRE

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Firebrick Pharma on TradingView ↗
Market value
A$7.1m
Last close × shares
Volume
2k
Shares, 9 Nov 2026

About Firebrick Pharma

Its shares trade on ASX under the ticker FRE.AX. It has been listed since 28 January 2022. In the fiscal year to 30 June 2026, it reported revenue of A$106,029 and a net loss of A$3.1m. At that date it held total assets of A$2.2m and shareholders' equity of A$1.7m.

Firebrick Pharma Ltd. is a pharmaceutical company, which engages in the development and commercialization of nasal spray treatment for the common cold based around the potential of povidone-iodine as an antimicrobial agent. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-01-28. The firm is engaged in developing and commercializing a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The company owns numerous granted and pending patents, including a core patent family that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold and a second patent family covering the prevention of pandemic viral diseases, including COVID-19. The company also has a third patent family covering the Nasodine formulation. The company is completing two major clinical trials: A Phase 2 trial of Nasodine in COVID-19 and a Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals. Positive Phase 3 trial results also be important for securing regulatory approvals and partnerships in markets outside Australia.

Figures and description from our data supplier, not checked against the company's own report.

More about Firebrick Pharma →

Latest on Firebrick Pharma

Our reporting

We have not reported on Firebrick Pharma yet.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Firebrick Pharma's ticker?

Firebrick Pharma trades as FRE.AX on ASX, under ISIN AU0000197352.

What was Firebrick Pharma's last closing price?

0.03 on 9 Nov 2026. The figure is in AUD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.